Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABER-C: Bismuth Subsalicylate for Stool Frequency in COVID-19
NCT04811339Phase 4Completed
- Sponsor
- University of Cincinnati
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bismuth subsalicylate in coronavirus disease 2019 (COVID-19), sponsored by University of Cincinnati. Started Oct 2020; status: completed.
02
Drugs
bismuth subsalicylate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04811339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811339.